摘要
目的探讨硫普罗宁治疗重度非酒精性脂肪性肝病(NAFLD)的临床疗效。方法选取重度非酒精性脂性肪肝病患者30例,测定患者及30例健康对照者的体质量指数、内毒素、瘦素、IL-6、IL-8水平。评价重度非酒精性脂肪性肝病患者采用硫普罗宁治疗3个月后,内毒素、瘦素、ALT、IL-6、IL-8的水平变化。结果与对照组比较,非酒精性脂肪性肝病患者内毒素升高,伴随内毒素水平升高,瘦素、ALT、IL-6、IL-8在非酒精性脂肪性肝病患者中也明显升高(P<0.05)。硫普罗宁治疗后,患者上述指标明显下降。结论 NAFLD患者存在肠源性内毒素血症,瘦素、IL-6、IL-8等细胞因子在非酒精性脂肪性肝病发病中具有重要的致病作用,硫普罗宁可明显改善内毒素血症,通过降低瘦素、IL-6、IL-8等细胞因子,治疗非酒精性脂肪性肝病安全、有效。
Objective To observe the clinical efficacy of Tiopronin in treatment of non-alcoholic fatty liver disease（NAFLD）.Methods Thirty patients with severe non-alcoholic fatty liver disease and 30 healthy controls were recruited.Those patients with severe NAFLD were treated with Tiopronin for 3 months.BMI,endotoxin,leptin,IL-6,ALT and IL-8 levels were measured before and after treatment.Results Compared with healthy controls,endotoxin,leptin,ALT,IL-6 and IL-8 levels were increased significantly（P0.05）.Compared with the NAFLD patients before treatment,endotoxin,leptin,IL-6 and IL-8 levels were decreased after teratment（P0.05）.There were significant difference in endotoxin,leptin,IL-6 and IL-8 levels between the therapy group and the control group. Conclusion Nonalcoholic fatty liver disease accompanies intestinal endotoxemia.Leptin,IL-6 and IL-8 have played important roles in the pathogenesis and progression of non-alcoholic fatty liver disease.Tiopronin could decrease the levels of the endotoxin,leptin,IL-6 and IL-8.Tiopronin is safe in the treatment of non-alcoholic fatty liver disease.
出处
《胃肠病学和肝病学杂志》
CAS
2011年第2期118-120,共3页
Chinese Journal of Gastroenterology and Hepatology
